Saiid Zarrabian
Known title: Head of Strategic PartnershipsCIK: 0001495521
Saiid Zarrabian's purchase track record
Saiid Zarrabian has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/6/2021 | HURA | $31K | -44.2% | -73.7% | -10.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| HURA | ▲ Buy | Open Market | 38,109 | $24K | 12/7/2021 | View on chart |
| HURA | ▲ Buy | Open Market | 11,891 | $7K | 12/6/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
HURA Secures U.S. Patent for DOR Antagonist Delivery
TuHURA Biosciences has been granted a U.S. patent covering the administration of DOR antagonists. The approval protects the company’s delivery technology and could support future drug development or licensing deals. The patent may strengthen HURA’s intellectual property portfolio and provide a competitive edge in the field of opioid receptor research.
HURA Secures U.S. Patent for DOR Antagonist Delivery. TuHURA Biosciences has been granted a U.S. patent covering the administration of DOR antagonists. The approval protects the company’s delivery technology and could support future drug development or licensing deals. The patent may strengthen HURA’s intellectual property portfolio and provide a competitive edge in the field of opioid receptor research.